White House drops FDA commissioner nominee Dr. Heidi Overton
When she was initially nominated, pro-life groups had called for Overton to restore safeguards on the abortion drug mifepristone.

Dr. Heidi Overton, whose pro-life views reportedly were among concerns of a number of GOP senators, is no longer the nominee for commissioner of the Food and Drug Administration (FDA).
ABC News reported Nov. 17 that a White House official, who was not named in the report, confirmed that the administration had dropped the nomination earlier this week, first reported by Axios. Overton received the nomination from President Donald Trump in August to succeed FDA commissioner Marty Makary, who resigned in May after a 13-month tenure.
Overton’s nomination withdrawal was celebrated by the pro-abortion Center for Reproductive Rights, which described Overton as an “anti-abortion extremist.” The organization had launched an initiative for citizens to urge their senators to vote against her, saying that Overton would have authority over the agency regulating abortion drugs for the entire country. The organization highlighted that Overton had called abortion “corrosive” and said abortion drugs are dangerous to women, and had called the overturning of Roe v. Wade a “huge victory.”
Pro-life groups have been urging the FDA to restore more regulations to the abortion drug mifepristone, amid safety concerns for women who take them and the death threat they pose to unborn children.
According to ABC News, several GOP senators were concerned with Overton’s views on abortion, vaccines, and vaping. The nomination drop came just before Overton was due for a vote in the Senate Health, Education, Labor, and Pensions (HELP) committee this week.
In a Nov. 17 statement, committee chair Sen. Bill Cassidy, R-La., outlined the repercussions of the White House’s decision to withdraw the nomination, adding that in his opinion there was a “viable confirmation path” for Overton.
The White House said it abandoned the path “because she did not have the votes to pass,” which Cassidy said “was odd as I was having productive conversations with members.”
“I believe she would have had the votes to pass out of committee and pass the full Senate,” Cassidy added. “My conversations with her convinced me she would follow the science and push back against decisions that put Americans’ health at risk.”
“The last issue was that pro-life Senators sought final assurances from the Administration regarding the Administration’s commitment to life issues,” Cassidy added. “The Administration withdrew Dr. Overton rather than make such commitments. Unfortunately, with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats.”










Comments